Physician profile
Michael D Dibella
NPI 1760471072
$1,620.55
in general payments reported to CMS, 2019-2025
14 companies · $50.38 in 2025
The $50.38 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $97.50 · 2021: $33.13 · 2022: $456 · 2023: $319 · 2024: $320 · 2025: $50.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.38 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $376.92 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.62 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $249.53 | 2019-2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $136.95 | 2019-2024 | Definity |
| Astellas Pharma US INC | $121.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.34 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $84.92 | 2022-2025 | Lokelma, Farxiga |
| Csl Behring | $80.00 | 2024 | Kcentra |
| Gilead Sciences, INC. | $47.68 | 2019 | |
| Biotronik INC. | $34.50 | 2022 | |
| Pfizer INC. | $23.67 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $17.44 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $17.15 | 2024 | |
| Amarin Pharma, INC. | $16.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dibella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.